β-Amyloid-mediated vasoactivity and vascular endothelial damage
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Deposits of beta-amyloid are apparent in ageing and Alzheimer's disease, but the role of this peptide in neurodegeneration is unclear. The free-radical theory of ageing may also account for Alzheimer-type degeneration and consequently links between free-radical generation and beta-amyloid have been sought. We demonstrate here that beta-amyloid interacts with endothelial cells on blood vessels to produce and excess of superoxide radicals, with attendant alterations in endothelial structure and function. The superoxide radical can scavenge endothelium-derived relaxing factor and produce potent oxidizing agents, which can cause lipid peroxidation and other degenerative changes. The alterations in vascular tone and endothelial damage are prevented by the oxygen-radical-scavenging enzyme superoxide dismutase. These observations suggest a normal vasoactive role for beta-amyloid as well as a mechanism by which beta-amyloid may play a role in vascular abnormalities and neurodegeneration mediated by free radicals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is a potent vasoconstrictor113,114 and suppresses endothelium-dependent responses, functional hyperemia, and cerebrovascular autoregulation.115–117”
In the citing paper
“As shown by pharmacological studies, these high concentrations of A b may impair local BBB integrity (58-59), which in turn may contaminate brain ISF with blood and/or plasma that possesses A b -degrading activity (48)”
From Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier (2000) · cites this paper as [59]
In the citing paper
“Aβ4 constrict isolated cerebral and systemic blood vessels (Niwa et al., 2001; Paris et al., 2003; Thomas et al., 1996)”
From The Pathobiology of Vascular Dementia (2013) · cites this paper as Thomas et al., 1996
Citations
Cites
Furchgott, R. F., & Zawadzki, J. V. (1980) · Nature · doi:10.1038/288373a0 · Cited by 12,064
Lipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., & Stamler, J. S. (1993) · Nature · doi:10.1038/364626a0 · Cited by 2,433
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975
Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
β-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease
Mattson, M. P., Barger, S. W., Cheng, B., Lieberburg, I., Smith-Swintosky, V. L., & Rydel, R. E. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90009-b · Cited by 518
PGH synthase and lipoxygenase generate superoxide in the presence of NADH or NADPH.
Kukreja, R. C., Kontos, H. A., Hess, M. L., & Ellis, E. F. (1986) · Circulation Research · doi:10.1161/01.res.59.6.612 · Cited by 487
Bu�e, L., Hof, P. R., Bouras, C., Delacourte, A., Perl, D. P., Morrison, J. H., & Fillit, H. M. (1994) · Acta Neuropathologica · doi:10.1007/bf00294173 · Cited by 334
Scholz, W. (1938) · Zeitschrift für die gesamte Neurologie und Psychiatrie · doi:10.1007/bf02890989 · Cited by 180
Soluble β-Amyloid Induction of Alzheimer's Phenotype for Human Fibroblast K + Channels
Etcheberrigaray, R., Ito, E., Kim, C. S., & Alkon, D. L. (1994) · Science · doi:10.1126/science.8146663 · Cited by 167
Untangling the pathophysio-chemistry of β-amyloid
Mattson, M. P. (1995) · Nature Structural & Molecular Biology · doi:10.1038/nsb1195-926 · Cited by 41
Research works printed but not linked: 2
- Davignon, J., Gregg, R. & Sing, C. Atherosclerosis 8, 1–21 (1988).
- Tomimoto, H., Nakimura, S., Wakita, H., Kimura, J. & Akiguchi, I. J. Cereb. Blood Flow Metab. 14, 563–573 (1994).
Cited by
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
“Arterial Component Ab is a potent vasoconstrictor in cerebral circulation (Thomas et al., 1996).”
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Rasch, B., & Born, J. (2013) · Physiological Reviews · doi:10.1152/physrev.00032.2012 · Cited by 2,783
The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease
Iadecola, C. (2017) · Neuron · doi:10.1016/j.neuron.2017.07.030 · Cited by 2,480
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases
Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M., & Stefani, M. (2002) · Nature · doi:10.1038/416507a · Cited by 2,434
“In other cases, particularly the degenerative neurological diseases, it appears likely that impairment of cellular function is directly linked to the interaction of protein aggregates with cellular components”
BackgroundOxidative stress hypothesis in Alzheimer’s disease
Markesbery, W. R. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00629-6 · Cited by 2,383
Neurovascular regulation in the normal brain and in Alzheimer's disease
Iadecola, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1387 · Cited by 2,213
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
The Pathobiology of Vascular Dementia
Iadecola, C. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.008 · Cited by 1,857
“Ab1 40 constrict isolated cerebral and systemic blood vessels (Niwa et al., 2001; Paris et al., 2003; Thomas et al., 1996), whereas application of Ab1 40 to the exposed cerebral cortex of mice reduces CBF and impairs the increase in CBF induced by endothelium-dependent vasodilators and functional…”
Stefani, M., & Dobson, C. M. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0464-5 · Cited by 1,651
“the interactions of the aggregated proteins with cellular components [21, 22].”
BackgroundRAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Hofman, A., Ott, A., Breteler, M. M., Bots, M. L., Slooter, A. J., van Harskamp, F., van Duijn, C. N., Van Broeckhoven, C., & Grobbee, D. E. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09328-2 · Cited by 1,062
Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease
Kisler, K., Nelson, A. R., Montagne, A., & Zlokovic, B. V. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.48 · Cited by 1,243
Oxidative stress and Alzheimer disease
Christen, Y. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.2.621s · Cited by 1,158
Amyloid β-Protein and the Genetics of Alzheimer's Disease
Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18295 · Cited by 799
Regulation of the Cerebral Circulation: Role of Endothelium and Potassium Channels
FARACI, F. M., & HEISTAD, D. D. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.1.53 · Cited by 780
Neurovascular mechanisms of Alzheimer's neurodegeneration
Zlokovic, B. V. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.02.001 · Cited by 770
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes
Nortley, R., Korte, N., Izquierdo, P., Hirunpattarasilp, C., Mishra, A., Jaunmuktane, Z., Kyrargyri, V., Pfeiffer, T., Khennouf, L., Madry, C., et al. (2019) · Science · doi:10.1126/science.aav9518 · Cited by 682
Serum Total Cholesterol, Apolipoprotein E {FC12}e4 Allele, and Alzheimer’s Disease
Notkola, I.-L., Sulkava, R., Pekkanen, J., Erkinjuntti, T., Ehnholm, C., Kivinen, P., Tuomilehto, J., & Nissinen, A. (1998) · Neuroepidemiology · doi:10.1159/000026149 · Cited by 669
Modelling of the blood–brain barrier in drug discovery and development
Cecchelli, R., Berezowski, V., Lundquist, S., Culot, M., Renftel, M., Dehouck, M.-P., & Fenart, L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2368 · Cited by 618
Genetic analysis of ageing: role of oxidative damage and environmental stresses
Martin, G. M., Austad, S. N., & Johnson, T. E. (1996) · Nature Genetics · doi:10.1038/ng0596-25 · Cited by 646
Chlorinative stress: An under appreciated mediator of neurodegeneration?
Yap, Y. W., Whiteman, M., & Cheung, N. S. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2006.06.013 · Cited by 570
The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia
Iadecola, C. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0718-6 · Cited by 557
“Similarly, Ab is a potent vasoconstrictor [ 111 ], and impairs the fundamental mechanisms regulating the cerebral circulation [45, 76, 77].”
The Aldo-Keto Reductase Superfamily and its Role in Drug Metabolism and Detoxification
Barski, O. A., Tipparaju, S. M., & Bhatnagar, A. (2008) · Drug Metabolism Reviews · doi:10.1080/03602530802431439 · Cited by 542
“…products Oxidative stress has emerged as a key metabolic disturbance associated with the development of several disease states such as diabetes mellitus, Alzheimer’s disease, atherosclerosis and heart failure (Brownlee, 2001; Glass and Witztum, 2001; Thomas et al., 1996; Srivastava et al., 2002).”
BackgroundOtt, A., Slooter, A., Hofman, A., van Harskamp, F., Witteman, J., Van Broeckhoven, C., van Duijn, C., & Breteler, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07541-7 · Cited by 535
Hamilton, N. B. (2010) · Frontiers in Neuroenergetics · doi:10.3389/fnene.2010.00005 · Cited by 513
“The presence of β-amyloid produces vasoconstriction, endothelial cell damage and a decrease in cerebral blood flow in larger blood vessels (Thomas et al., 1996; Niwa et al., 2001), and also reduces the reactivity of cerebral blood vessels to neuronal activity or to endothelium-dependent…”
BackgroundPlasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study
van Oijen, M., Hofman, A., Soares, H. D., Koudstaal, P. J., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70501-4 · Cited by 458
Redox‐Active Metals, Oxidative Stress, and Alzheimer's Disease Pathology
HUANG, X., MOIR, R. D., TANZI, R. E., BUSH, A. I., & ROGERS, J. T. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.012 · Cited by 425
Mitochondria, free radicals, and neurodegeneration
Beal, M. F. (1996) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(96)80100-0 · Cited by 424
Increased F 2 ‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo
Pratico, D., Lee, V. M.-Y., Trojanowski, J. Q., Rokach, J., & Fitzgerald, G. A. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.15.1777 · Cited by 405
Alzheimer’s Disease and Vascular Aging
Cortes-Canteli, M., & Iadecola, C. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.062 · Cited by 400
SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein
Iadecola, C., Zhang, F., Niwa, K., Eckman, C., Turner, S. K., Fischer, E., Younkin, S., Borchelt, D. R., Hsiao, K. K., & Carlson, G. A. (1999) · Nature Neuroscience · doi:10.1038/5715 · Cited by 399
Coraci, I. S., Husemann, J., Berman, J. W., Hulette, C., Dufour, J. H., Campanella, G. K., Luster, A. D., Silverstein, S. C., & El Khoury, J. B. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64354-4 · Cited by 398
Chapter 7 Protein Oxidation Processes in Aging Brain
Butterfield, D. A., & Stadtman, E. R. (1997) · Advances in cell aging and gerontology · doi:10.1016/s1566-3124(08)60057-7 · Cited by 390
Bastianetto, S., Ramassamy, C., Doré, S., Christen, Y., Poirier, J., & Quirion, R. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00069.x · Cited by 379
Prefibrillar Amyloid Protein Aggregates Share Common Features of Cytotoxicity
Bucciantini, M., Calloni, G., Chiti, F., Formigli, L., Nosi, D., Dobson, C. M., & Stefani, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400348200 · Cited by 369
Hock, C., Villringer, K., Müller-Spahn, F., Wenzel, R., Heekeren, H., Schuh-Hofer, S., Hofmann, M., Minoshima, S., Schwaiger, M., Dirnagl, U., et al. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00122-4 · Cited by 377
The role of oxidative stress in the toxicity induced by amyloid β-peptide in Alzheimer’s disease
Miranda, S., Opazo, C., Larrondo, L. F., Muñoz, F. J., Ruiz, F., Leighton, F., & Inestrosa, N. C. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00015-0 · Cited by 369
Pathophysiology of the Neurovascular Unit: Disease Cause or Consequence?
Stanimirovic, D. B., & Friedman, A. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.25 · Cited by 346
“Ab in turn stimulates ROS production in endothelial cells; ROS scavenge endothelium-derived relaxing factor (NO) thus impairing resting cerebrovascular tone and NO-dependent dilatation (Thomas et al, 1996).”
BackgroundBlood—Brain Barrier Permeability Precedes Senile Plaque Formation in an Alzheimer Disease Model
UJIIE, M., DICKSTEIN, D. L., CARLOW, D. A., & JEFFERIES, W. A. (2003) · Microcirculation · doi:10.1038/sj.mn.7800212 · Cited by 351
“When excised rat aorta was treated with A, endothelial cells produced superoxide radicals ( 24 ), and a free radical formation inhibitor, N-tert-butyl-(2 sulfophenyl)nitrone, protected primary brain endothelial cell cultures against A toxicity (3).”
BackgroundPlasma β-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy
Gurol, M. E., Irizarry, M. C., Smith, E. E., Raju, S., Diaz-Arrastia, R., Bottiglieri, T., Rosand, J., Growdon, J. H., & Greenberg, S. M. (2006) · Neurology · doi:10.1212/01.wnl.0000191403.95453.6a · Cited by 339
Cerebral amyloid angiopathy and cognitive function: The HAAS autopsy study
Pfeifer, L. A., White, L. R., Ross, G. W., Petrovitch, H., & Launer, L. J. (2002) · Neurology · doi:10.1212/wnl.58.11.1629 · Cited by 338
Paradis, E., Douillard, H., Koutroumanis, M., Goodyer, C., & LeBlanc, A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-23-07533.1996 · Cited by 282
“The underlying mechanisms mediating Ab neurotoxicity are attributed to either oxidative stress (Behl et al., 1994; Thomas et al., 1996 ) or the destabilization of intracellular calcium levels (Mattson et al., 1992).”
Park, L., Zhou, P., Pitstick, R., Capone, C., Anrather, J., Norris, E. H., Younkin, L., Younkin, S., Carlson, G., McEwen, B. S., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711568105 · Cited by 332
“In vitro and in vivo studies have demonstrated that A enhances vasoconstriction, impairs responses to vasodilators, and reduces cerebral blood flow (CBF) (4, 5).”
BackgroundAmyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma
Biere, A. L., Ostaszewski, B., Stimson, E. R., Hyman, B. T., Maggio, J. E., & Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32916 · Cited by 331
Vascular risk factors, cognitve decline, and dementia
Hanon, O. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1839 · Cited by 313
“Likewise, endothelial lesions in AD have been related to the location and number of senile plaques (Kalaria and Hedera 1996) and it has been reported that beta amyloid could interact with vascular endothelial cells to produce an excess of free radicals (Thomas et al 1996).”
Paul, J., Strickland, S., & Melchor, J. P. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070304 · Cited by 319
Low blood pressure and the risk of dementia in very old individuals
Verghese, J., Lipton, R. B., Hall, C. B., Kuslansky, G., & Katz, M. J. (2003) · Neurology · doi:10.1212/01.wnl.0000098934.18300.be · Cited by 309
Incidence of Cerebral Microbleeds in the General Population: The Rotterdam Scan Study
Poels, M. M. F., Ikram, M. A., van der Lugt, A., Hofman, A., Krestin, G. P., Breteler, M. M. B., & Vernooij, M. W. (2011) · Stroke · doi:10.1161/strokeaha.110.607184 · Cited by 294
Amyloid Angiopathy–Related Vascular Cognitive Impairment
Greenberg, S. M., Gurol, M. E., Rosand, J., & Smith, E. E. (2004) · Stroke · doi:10.1161/01.str.0000143224.36527.44 · Cited by 298
Atwood, C. S., Obrenovich, M. E., Liu, T., Chan, H., Perry, G., Smith, M. A., & Martins, R. N. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00174-7 · Cited by 293
“presence of SOD (Thomas et al., 1996), catalytic synthetic O2- .”
BackgroundUpdate on hypertension and Alzheimer's disease
Skoog, I., & Gustafson, D. (2006) · Neurological Research · doi:10.1179/016164106x130506 · Cited by 294
β-Amyloid, Blood Vessels, and Brain Function
Smith, E. E., & Greenberg, S. M. (2009) · Stroke · doi:10.1161/strokeaha.108.536839 · Cited by 293
Rogers, J. T., Leiter, L. M., McPhee, J., Cahill, C. M., Zhan, S.-S., Potter, H., & Nilsson, L. N. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6421 · Cited by 290
Niwa, K., Kazama, K., Younkin, L., Younkin, S. G., Carlson, G. A., & Iadecola, C. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00022.2002 · Cited by 286
“First, the alterations of endothelium-dependent relaxation produced by synthetic A applied to the cerebral cortex of normal mice or to isolated blood vessels are abrogated by ROS scavengers (27, 30, 38).”
BackgroundCalabrese, V., Bates, T. E., & Stella, A. M. G. (2000) · Neurochemical Research · doi:10.1023/a:1007604414773 · Cited by 284
“Additional evidence regarding the oxidative hypothesis of AD arise from the finding that vitamin E was found to protect PC 12 cells and neurons against A β-induced toxicity (204) as well as non neuronal cells such as lens (205), smooth muscle (206), and vascular endothelial tissue (207).”
Reply to: 'Clearance of amyloid β-peptide from brain: transport or metabolism?'
Iwata, N., Tsubuki, S., Hama, E., Takaki, Y., Shirotani, K., & Saido, T. C. (2000) · Nature Medicine · doi:10.1038/77399 · Cited by 285
The Pericyte: A Forgotten Cell Type with Important Implications for Alzheimer's Disease?
Winkler, E. A., Sagare, A. P., & Zlokovic, B. V. (2014) · Brain Pathology · doi:10.1111/bpa.12152 · Cited by 278
Hanon, O., Haulon, S., Lenoir, H., Seux, M.-L., Rigaud, A.-S., Safar, M., Girerd, X., & Forette, F. (2005) · Stroke · doi:10.1161/01.str.0000181771.82518.1c · Cited by 280
Lee, J.-T., Xu, J., Lee, J.-M., Ku, G., Han, X., Yang, D.-I., Chen, S., & Hsu, C. Y. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200307017 · Cited by 280
Multifunctional role of astrocytes as gatekeepers of neuronal energy supply
Stobart, J. L., & Anderson, C. M. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00038 · Cited by 264
“This is linked to reduced free NO and vasoconstriction (Thomas et al., 1996; Niwa et al., 2001), and suggests that Aβ accumulation may alter the functional neurovascular unit.”
BackgroundGovindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 275
Blood–Brain Barrier Dysfunction in a 3D In Vitro Model of Alzheimer's Disease
Shin, Y., Choi, S. H., Kim, E., Bylykbashi, E., Kim, J. A., Chung, S., Kim, D. Y., Kamm, R. D., & Tanzi, R. E. (2019) · Advanced Science · doi:10.1002/advs.201900962 · Cited by 274
Amyloid β42Activates a G-Protein-Coupled Chemoattractant Receptor, FPR-Like-1
Le, Y., Gong, W., Tiffany, H. L., Tumanov, A., Nedospasov, S., Shen, W., Dunlop, N. M., Gao, J.-L., Murphy, P. M., Oppenheim, J. J., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-j0003.2001 · Cited by 270
“Moreover, the role of FPRL1 in Ab-induced direct neurotoxicity (Lambert et al., 1998), vasculopathy (Thomas et al., 1996), or activation of astrocytes (Johnstone et al., 1999) is presently unknown and merits investigation.”
BackgroundCalabrese, V., Scapagnini, G., Giuffrida Stella, A. M., Bates, T. E., & Clark, J. B. (2001) · Neurochemical Research · doi:10.1023/a:1010955807739 · Cited by 263
White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage
Smith, E. E., Gurol, M. E., Eng, J. A., Engel, C. R., Nguyen, T. N., Rosand, J., & Greenberg, S. M. (2004) · Neurology · doi:10.1212/01.wnl.0000142966.22886.20 · Cited by 253
Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders
Carmeliet, P., & Storkebaum, E. (2002) · Seminars in Cell & Developmental Biology · doi:10.1006/scdb.2001.0290 · Cited by 252
Rozovsky, I., Finch, C. E., & Morgan, T. E. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00169-3 · Cited by 254
Neurovascular Dysfunction and Faulty Amyloid -Peptide Clearance in Alzheimer Disease
Sagare, A. P., Bell, R. D., & Zlokovic, B. V. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011452 · Cited by 251
“For example, it has been shown that Ab constricts cerebral arteries (Thomas et al. 1996), and that endothelium-dependent regulation of cortical microcirculation is diminished in a mouse model of AD before Ab accumulation (Iadecola et al. 1999).”
BackgroundAβ1–40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation
Niwa, K., Younkin, L., Ebeling, C., Turner, S. K., Westaway, D., Younkin, S., Ashe, K. H., Carlson, G. A., & Iadecola, C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.17.9735 · Cited by 244
Park, L., Anrather, J., Zhou, P., Frys, K., Pitstick, R., Younkin, S., Carlson, G. A., & Iadecola, C. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5207-04.2005 · Cited by 244
Neurovascular Unit Dysfunction and Neurodegenerative Disorders
Yu, X., Ji, C., & Shao, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00334 · Cited by 244
“The accumulation of Aβ deteriorates cerebrovascular function, increases arterial vasoconstriction, and reduces CBF (Thomas et al., 1996; Niwa et al., 2000).”
BackgroundThe Role of Drug Transporters at the Blood-Brain Barrier
de Boer, A. G., van der Sandt, I. C. J., & Gaillard, P. J. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140204 · Cited by 238
Mackic, J. B., Stins, M., McComb, J. G., Calero, M., Ghiso, J., Kim, K. S., Yan, S. D., Stern, D., Schmidt, A. M., Frangione, B., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2029 · Cited by 242
BRETELER, M. M. B. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06399.x · Cited by 234
Amyloid-β Peptides Are Cytotoxic to Oligodendrocytes
Xu, J., Chen, S., Ahmed, S. H., Chen, H., Ku, G., Goldberg, M. P., & Hsu, C. Y. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-01-j0001.2001 · Cited by 230
“Although Ab has been shown to be cytotoxic to neurons (Yankner et al., 1989; Behl et al., 1994) and endothelial cells (Thomas et al., 1996), the effect of Ab toxicity on oligodendrocytes (OLGs) has not been studied.”
BackgroundStackman, R. W., Eckenstein, F., Frei, B., Kulhanek, D., Nowlin, J., & Quinn, J. F. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00399-6 · Cited by 230
Reactive oxygen species and Alzheimer's disease
Multhaup, G., Ruppert, T., Schlicksupp, A., Hesse, L., Beher, D., Masters, C. L., & Beyreuther, K. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00062-2 · Cited by 227
Bhatia, R., Lin, H., & Lal, R. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.9.1233 · Cited by 226
Kelleher, R. J., & Soiza, R. L. (2013) · Europe PMC (PubMed Central) · Cited by 271
Wyss-Coray, T., Lin, C., Sanan, D. A., Mucke, L., & Masliah, E. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64713-x · Cited by 224
Kovacic, J. C., Moreno, P., Nabel, E. G., Hachinski, V., & Fuster, V. (2011) · Circulation · doi:10.1161/circulationaha.110.009118 · Cited by 223
Farkas, E., De Jong, G. I., de Vos, R. A. I., Jansen Steur, E. N. H., & Luiten, P. G. M. (2000) · Acta Neuropathologica · doi:10.1007/s004010000195 · Cited by 217
“Prominent examples are β-amyloid action on endothelial cells leading to endothelial dysfunction [ 39 , 40] or the effect of oxygen free radicals on endothelial cells causing chromosomal aberrations and the induction of micronuclei [26].”
BackgroundGuo, Z., Fratiglioni, L., Zhu, L., Fastbom, J., Winblad, B., & Viitanen, M. (1999) · Archives of Neurology · doi:10.1001/archneur.56.8.991 · Cited by 215
Role of Vascular Risk Factors and Vascular Dysfunction in Alzheimer's Disease
Dickstein, D. L., Walsh, J., Brautigam, H., Stockton, S. D., Gandy, S., & Hof, P. R. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20155 · Cited by 155
Cellular Senescence, Vascular Disease, and Aging: Part 1 of a 2-Part Review
Kovacic, J. C., Moreno, P., Hachinski, V., Nabel, E. G., & Fuster, V. (2011) · Circulation · doi:10.1161/circulationaha.110.007021 · Cited by 205
Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm
Lal, R., Lin, H., & Quist, A. P. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.04.021 · Cited by 205
“Such an increased cellular calcium level can change the local micromechanical properties of cells [16] and induce cytoskeletal reorganization, one of the earliest detectable changes observed in neurodegenerative disorders such as AD [17].”
BackgroundZhang, F., Eckman, C., Younkin, S., Hsiao, K. K., & Iadecola, C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-20-07655.1997 · Cited by 205
“This possibility is supported by the observation that in isolated systemic vessels Ab reduces the relaxation produced by ACh ( Thomas et al., 1996 ).”
BackgroundInfluentialMonoamine oxidase-B inhibitors in the treatment of Alzheimers disease
Thomas, T. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00100-7 · Cited by 201
Self-citationAβ-peptides enhance vasoconstriction in cerebral circulation
Niwa, K., Porter, V. A., Kazama, K., Cornfield, D., Carlson, G. A., & Iadecola, C. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.281.6.h2417 · Cited by 202
Wheeler, M. J., Dempsey, P. C., Grace, M. S., Ellis, K. A., Gardiner, P. A., Green, D. J., & Dunstan, D. W. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.04.001 · Cited by 183
Lang, D., Kredan, M. B., Moat, S. J., Hussain, S. A., Powell, C. A., Bellamy, M. F., Powers, H. J., & Lewis, M. J. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.2.422 · Cited by 199
Shinozaki, K., Ayajiki, K., Nishio, Y., Sugaya, T., Kashiwagi, A., & Okamura, T. (2004) · Hypertension · doi:10.1161/01.hyp.0000111136.86976.26 · Cited by 197
Amyloid-β Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients
Patton, R. L., Kalback, W. M., Esh, C. L., Kokjohn, T. A., Van Vickle, G. D., Luehrs, D. C., Kuo, Y.-M., Lopez, J., Brune, D., Ferrer, I., et al. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.060269 · Cited by 192
Cullen, K. M., Kócsi, Z., & Stone, J. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.10.016 · Cited by 197
Metadata
- Authors
- Thomas, T., Thomas, G., McLendon, C., Sutton, T., & Mullan, M.
- Affiliations
- University of South Florida (US)
- Venue
- Nature
- Published
- 1996-03
- Volume
- 380
- Issue
- 6570
- Pages
- 168-171
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1990427131
- Cited by
- 703
- References
- 12
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 18 · 2023: 22 · 2022: 9 · 2021: 15 · 2020: 24 · 2019: 19 · 2018: 5 · 2017: 12 · 2016: 22 · 2015: 26 · 2014: 16 · 2013: 26 · 2012: 13
- FWCI
- 26.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
- Keywords
- amyloid-beta, Alzheimer's disease, vascular endothelial cells, superoxide, free radicals, superoxide dismutase, endothelium-derived relaxing factor, lipid peroxidation, vascular tone, neurodegeneration, aging, oxidative stress
- MeSH terms
- Acetylcholine, Alzheimer Disease, Animals, Aorta, Blood Vessels, Endothelium, Vascular, Nerve Degeneration, Phenylephrine, Superoxides, Vasoconstriction, Vasoconstrictor Agents, Vasodilator Agents, Amyloid beta-Peptides, Rats, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.